SCHEMBL16667808

SCHEMBL16667808

COc1cc(OC)cc(-c2cc3cnc(Cl)nc3cc2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 12/20 0.55
▸ KDM4E B2RXH2 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ SRC P12931 1/20 0.41
▸ FGFR2 P21802 3/20 0.40
▸ FGFR4 P22455 3/20 0.40
▸ FGFR3 P22607 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KDR P35968 2/20 0.39
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP1A1 P04798 2/20 0.38
▸ CYP1B1 Q16678 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29385006 1.00 FGFR1 (0.55) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL15413235 0.87 KDM4E (0.65) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL29385053 0.87 KDM4E (0.65) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
Hydrochloric Acid SCHEMBL28010166 0.86 KDM4E (0.63) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL31647846 0.86 FGFR1 (0.59) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL16668439 0.86 FGFR1 (0.52) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL29386366 0.86 FGFR1 (0.52) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL31647808 0.82 FGFR1 (0.49) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL24335187 0.80 KDM4E (0.56) FGFR1KDM4EALDH1A1SMN1; SMN2SRC
SCHEMBL31648508 0.80 PIN1 (0.50) FGFR1KDM4EALDH1A1SMN1; SMN2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3395814-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2022-04-06 — — EP disclosed
EP-3395814-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2022-04-06 — — EP disclosed
CN-110028491-B Fibroblast growth factor receptor inhibitors 缆图药品公司 2022-02-11 — — CN disclosed
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2021-11-11 — — US disclosed
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2021-11-11 — — US disclosed
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2020-12-29 — — US disclosed
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2020-12-29 — — US disclosed
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2020-04-09 — — US disclosed
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2020-04-09 — — US disclosed
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-03-05 — — US disclosed
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-06-22 — — US disclosed
US-9434700-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 2016-09-06 — — US disclosed
US-9434700-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 2016-09-06 — — US disclosed
US-9434700-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION 2016-09-06 — — US disclosed
EP-3060560-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR Blueprint Medicines Corporation (US) 2016-08-31 — — EP disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 — — US disclosed
WO-2015061572-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 — — WO disclosed
WO-2015061572-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 — — WO disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 — — US disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 FGFR1 2/4885KDM4E 976/4885ALDH1A1 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback